[go: up one dir, main page]

WO2008149177A3 - Marine lipid compositions and uses thereof - Google Patents

Marine lipid compositions and uses thereof Download PDF

Info

Publication number
WO2008149177A3
WO2008149177A3 PCT/IB2007/003097 IB2007003097W WO2008149177A3 WO 2008149177 A3 WO2008149177 A3 WO 2008149177A3 IB 2007003097 W IB2007003097 W IB 2007003097W WO 2008149177 A3 WO2008149177 A3 WO 2008149177A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid compositions
omega
marine lipid
compositions
marine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/003097
Other languages
French (fr)
Other versions
WO2008149177A2 (en
Inventor
Inge Bruheim
Hogne Hallaraker
Sebastiano Banni
Mikko Griinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aker Biomarine ASA
Original Assignee
Natural ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural ASA filed Critical Natural ASA
Anticipated expiration legal-status Critical
Publication of WO2008149177A2 publication Critical patent/WO2008149177A2/en
Publication of WO2008149177A3 publication Critical patent/WO2008149177A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)

Abstract

Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega- 3, increased tissue incorporation of omega-3 and reduced concentration of pro- inflammatory cytokines.
PCT/IB2007/003097 2006-05-05 2007-05-04 Marine lipid compositions and uses thereof Ceased WO2008149177A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US79802606P 2006-05-05 2006-05-05
US79802706P 2006-05-05 2006-05-05
US79803006P 2006-05-05 2006-05-05
US60/798,026 2006-05-05
US60/798,027 2006-05-05
US60/798,030 2006-05-05
US87209606P 2006-12-01 2006-12-01
US60/872,096 2006-12-01

Publications (2)

Publication Number Publication Date
WO2008149177A2 WO2008149177A2 (en) 2008-12-11
WO2008149177A3 true WO2008149177A3 (en) 2009-01-29

Family

ID=39168268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003097 Ceased WO2008149177A2 (en) 2006-05-05 2007-05-04 Marine lipid compositions and uses thereof

Country Status (1)

Country Link
WO (1) WO2008149177A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2153736B1 (en) * 2007-05-11 2017-04-19 Bizen Chemical Co., Ltd. Novel leukotriene receptor antagonist from marine sources
MX2012004977A (en) 2009-10-29 2012-11-06 Acasti Pharma Inc CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS.
PL2519332T3 (en) 2009-12-30 2014-08-29 Basf Pharma Callanish Ltd Simulated moving bed chromatographic separation process for the purification of polyunsaturated fatty acids
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
EP2883860B1 (en) 2013-12-11 2016-08-24 Novasep Process Chromatographic method for producing polyunsaturated fatty acids
US10975031B2 (en) 2014-01-07 2021-04-13 Novasep Process Method for purifying aromatic amino acids
EP3709817B2 (en) * 2017-11-17 2025-10-22 Hill's Pet Nutrition, Inc. Compositions comprising omega-3 polyunsaturated and medium chain fatty acids
CN110564787B (en) * 2019-08-02 2023-02-21 大渔华创(广州)海洋生物科技有限公司 Polyunsaturated fatty acid-rich blood phospholipid composition and preparation method thereof
CN110538185A (en) * 2019-10-09 2019-12-06 广东海洋大学深圳研究院 Application of sea cucumber phospholipids in the preparation of anti-inflammatory drugs
EP4611786A1 (en) * 2022-11-03 2025-09-10 Exerkine Corporation Fertility enhancement composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021335A1 (en) * 1991-05-30 1992-12-10 Kabi Pharmacia Ab Phospholipids
WO1996026287A1 (en) * 1995-02-24 1996-08-29 Goemar S.A. Enzymatic methods for polyunsaturated fatty acid enrichment
WO2006054183A2 (en) * 2004-11-17 2006-05-26 Natural Asa Enzymatically synthesized marine phospholipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021335A1 (en) * 1991-05-30 1992-12-10 Kabi Pharmacia Ab Phospholipids
WO1996026287A1 (en) * 1995-02-24 1996-08-29 Goemar S.A. Enzymatic methods for polyunsaturated fatty acid enrichment
WO2006054183A2 (en) * 2004-11-17 2006-05-26 Natural Asa Enzymatically synthesized marine phospholipids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOSOKAWA M ET AL: "PREPARATION OF THERAPEUTIC PHOSPHOLIPIDS THROUGH PORCINE PANCREATIC PHOSPHOLIPASE A2-MEDIATED ESTERIFICATION AND LIPOZYME-MEDIATED ACIDOLYSIS", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, SPRINGER, BERLIN, DE, vol. 72, no. 11, 1995, pages 1287 - 1291, XP008048478, ISSN: 0003-021X *

Also Published As

Publication number Publication date
WO2008149177A2 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
WO2008149177A3 (en) Marine lipid compositions and uses thereof
WO2009055568A3 (en) Liposomal vancomycin formulations
WO2007090393A3 (en) Microtablet-based pharmaceutical preparation
WO2010043415A3 (en) Whey protein compositions, methods and uses
WO2007101551A3 (en) Phospholipid complexes of curcumin having improved bioavailability
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
ZA200810741B (en) Methodes for the preparation of biologically active compounds in nanoparticulate form
WO2007066232A3 (en) Salts of fatty acids and methods of making and using thereof
ZA200804830B (en) Oil-in-water formulation of avermectins
WO2006131591A3 (en) An entacapone-containing oral dosage form
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
WO2008136865A3 (en) (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
EP1932533A4 (en) Composition for amelioration of body lipid
WO2006096518A3 (en) Improved gacyclidine formulations
WO2007070613A3 (en) Rifamycin analogs and uses thereof
UA88030C2 (en) Composition containing omega-3 fatty acids and omega-6 fatty acids for use in the treatment of dry eye syndrome
WO2008107771A3 (en) 2',3'-di-o-acyl-5-fluoronucleosides
CA2556520A1 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2010025011A8 (en) Formulations of canfosfamide and their preparation
ZA200710664B (en) Processes for the preparation of docetaxel
IL187855A0 (en) Processes for the preparation of docetaxel
WO2007117704A3 (en) Pure isomers of tritoqualine
EP1879013A4 (en) Method for the design of self-emulsifying drug formulations
WO2008136852A3 (en) Methods and compositions related to the structure and function of apobec3g
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07825397

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 07825397

Country of ref document: EP

Kind code of ref document: A2